M
Marcus V. Ortega Alves
Researcher at University of Texas MD Anderson Cancer Center
Publications - 5
Citations - 786
Marcus V. Ortega Alves is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Head and neck squamous-cell carcinoma & CCL5. The author has an hindex of 5, co-authored 5 publications receiving 683 citations. Previous affiliations of Marcus V. Ortega Alves include University of Pittsburgh & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
Curtis R. Pickering,Jiexin Zhang,Suk Young Yoo,Linnea Bengtsson,Shhyam Moorthy,David M. Neskey,Mei Zhao,Marcus V. Ortega Alves,Kyle Chang,Jennifer Drummond,Elsa Cortez,Tong Xin Xie,Di Zhang,Woonbok Chung,Jean Pierre J. Issa,Patrick A. Zweidler-McKay,Xifeng Wu,Adel K. El-Naggar,John N. Weinstein,Jing Wang,Donna M. Muzny,Richard A. Gibbs,Richard A. Gibbs,David A. Wheeler,Jeffrey N. Myers,Mitchell J. Frederick +25 more
TL;DR: Although genomic alterations are dominated by loss of tumor suppressor genes, 80% of patients harbored at least one genomic alteration in a targetable gene, suggesting that novel approaches to treatment may be possible for this debilitating subset of head and neck cancers.
Journal ArticleDOI
Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers
Curtis R. Pickering,Jiexin Zhang,David M. Neskey,Mei Zhao,Samar A. Jasser,Jiping Wang,Alexandra M. Ward,C. Jillian Tsai,Marcus V. Ortega Alves,Jane H. Zhou,Jennifer Drummond,Adel K. El-Naggar,Richard A. Gibbs,John N. Weinstein,David A. Wheeler,Jing Wang,Mitchell J. Frederick,Jeffrey N. Myers +17 more
TL;DR: Overall, tumors from young patients with SCCOT appear genomically similar to those of older patients withSCCOT, and the cause for the increasing incidence of young S CCOT remains unknown, indicating that the functional impact of smoking on carcinogenesis in SCCot is still poorly understood.
Journal ArticleDOI
Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Mayur Arvind Gadhikar,Maria Rita Sciuto,Marcus V. Ortega Alves,Curtis R. Pickering,Abdullah A. Osman,David M. Neskey,Mei Zhao,Alison L. Fitzgerald,Jeffrey N. Myers,Mitchell J. Frederick +9 more
TL;DR: This is the first report showing the ability of a Chk kinase inhibitor to sensitize TP53-deficient HNSCC to cisplatin in a synthetic lethal manner, which has significance given the frequency of TP53 mutations in this disease and because cis platin has become part of standard therapy for aggressive H NSCC tumors.
Journal ArticleDOI
A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma.
TL;DR: A novel xenograft model of acquired resistance to bevacizumab is established that converges on ERK signaling to upregulate FGF2, which then mediates evasion of anti-VEGF therapy, providing a new strategy on how to enhance the therapeutic efficacy of antiangiogenic therapy.
Journal ArticleDOI
Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma
Rekha Gyanchandani,Daisuke Sano,Daisuke Sano,Marcus V. Ortega Alves,Jonah D. Klein,Beth A. Knapick,Sanders Oh,Jeffrey N. Myers,Seungwon Kim +8 more
TL;DR: These results implicate IL-8 in mediating intrinsic resistance to bevacizumab in HNSCC and suggest co-targeting of VEGF andIL-8 may help overcome resistance and enhance therapeutic efficacy.